ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Takeda Pharmaceutical is collaborating with Anima Biotech to discover and develop small-molecule drugs for three neurological disease targets, including Huntington’s disease. Anima seeks to find molecules that can accelerate or slow messenger RNA translation and, as a result, increase or decrease the production of proteins encoded by mRNA. Anima will earn $120 million in up-front and preclinical research milestones and up to $1.1 billion in clinical and commercial milestones. Takeda has an option to expand the collaboration to include three more targets, earning Anima up to $1.2 billion more.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X